The TGA will decide before the end of the month whether textured breast implants will stay on the Australian market, after having been deemed unsafe by European regulators.

In December, textured breast implants manufactured by Allergan were withdrawn from the European market amid growing concerns from health authorities that they could pose a heightened risk of anaplastic large cell lymphoma.

To date, the TGA has reported a total of 72 Australian cases of anaplastic large cell lymphoma, all in women with textured or polyurethane implants.

“From now on, these medical devices can no longer be marketed in France and in Europe and [we have asked] Allergan to recall products in stock at all health facilities,” said the French regulator, the National Security Agency of Medicines and Health Products (ANSM).